NCT07081841

Brief Summary

This is an observational, long term, follow-up study for participants with Parkinson's disease (PD) or Multiple System Atrophy-Parkinsonian subtype (MSA-P) who participated in prior interventional studies with AB-1005. It is intended to better understand the long-term safety of AB-1005, how well tolerated it is and how long lasting the effects are.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
132

participants targeted

Target at P50-P75 for all trials

Timeline
145mo left

Started Sep 2025

Longer than P75 for all trials

Geographic Reach
1 country

2 active sites

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress5%
Sep 2025Mar 2038

First Submitted

Initial submission to the registry

June 9, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

July 23, 2025

Completed
1 month until next milestone

Study Start

First participant enrolled

September 4, 2025

Completed
12.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2037

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 30, 2038

Last Updated

October 2, 2025

Status Verified

September 1, 2025

Enrollment Period

12.1 years

First QC Date

June 9, 2025

Last Update Submit

September 29, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Long term safety and tolerability

    Measure of the occurrence of serious and non-serious adverse events

    Up to 10 years post surgery

Study Arms (2)

Participants with PD

Other: Observation

Participants with MSA-P

Other: Observation

Interventions

This is an observational study in which safety laboratories and non-invasive routine clinical assessments are conducted to gauge long term safety and efficacy.

Participants with MSA-PParticipants with PD

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Participants who have participated in interventional studies of AB-1005.

You may qualify if:

  • PD and MSA-P participants that are or were enrolled in an interventional AB-1005 study and provide informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

University of California San Francisco

San Francisco, California, 94143, United States

Location

Ohio State University

Columbus, Ohio, 43210, United States

Location

MeSH Terms

Conditions

Parkinson DiseaseMultiple System Atrophy

Interventions

Observation

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative DiseasesPrimary DysautonomiasAutonomic Nervous System Diseases

Intervention Hierarchy (Ancestors)

MethodsInvestigative Techniques

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 9, 2025

First Posted

July 23, 2025

Study Start

September 4, 2025

Primary Completion (Estimated)

September 30, 2037

Study Completion (Estimated)

March 30, 2038

Last Updated

October 2, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations